Key result
Catheter ablation and pharmacologic therapy are reviewed as treatment options for reentrant supraventricular arrhythmias, atrial fibrillation, atrial flutter, and atrial tachycardia.
Why the study?
Does catheter ablation improve outcomes compared to pharmacologic therapy in patients with supraventricular tachyarrhythmias?
Does catheter ablation improve outcomes compared to pharmacologic therapy in patients with supraventricular tachyarrhythmias?
This review discusses the evolving role of catheter ablation as a nonpharmacologic alternative to drug therapy for various supraventricular tachyarrhythmias.
Until recently, the only options available for treatment of supraventricular arrhythmias involved the use of drug therapy or cardiac surgery. However, over the past several years with the introduction of radiofrequency energy sources as well as steerable catheters, the clinician has a variety of additional nonpharmacologic options. This article reviews the use of pharmacologic therapy versus catheter ablation for the treatment of reentrant supraventricular arrhythmias, involving the atrioventricular junction and/or accessory atrioventricular connection, as well as arrhythmias emanating from the atria such as atrial fibrillation, atrial flutter, and atrial tachycardia.
No takes yet. Share an insight, caveat, or question.
Melvin M. Scheinman (2009) conducted a review in Supraventricular tachyarrhythmias. Catheter ablation vs. Pharmacologic therapy was evaluated. Catheter ablation and pharmacologic therapy are reviewed as treatment options for reentrant supraventricular arrhythmias, atrial fibrillation, atrial flutter, and atrial tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: